Hikma Pharmaceuticals

What they make

1 input Hikma Pharmaceuticals supplies

Click an input to see every good that depends on it, every country that produces it, and every other company in the supply chain.

Intelligence

What's known

Sourced claims about this company's role in supply chains, chokepoints, concentration, incidents, dual-use connections.

• Did you know2024

  A backbone of the American hospital drug supply is a family company founded in Jordan. Hikma Pharmaceuticals was started in 1978 in Amman by Samih Darwazah and is today a London-listed FTSE 100 firm — and one of the largest suppliers of generic sterile injectable medicines to U.S. hospitals. The propofol used to anesthetize surgical patients, the emergency drugs on crash carts, and a long list of oncology and critical-care injectables are supplied at scale by this Middle Eastern-rooted company. Almost no American patient or clinician realizes that a pharmaceutical company born in Jordan quietly sits in the critical path of operating-room and ICU medicine across the United States — a striking example of how globalized and geographically unexpected the supply of "essential" drugs has become.

  Hikma Pharmaceuticals PLC (HIK.L) ↗

• Chokepoint2024

  Generic sterile injectables are the single most shortage-prone category in American medicine. They are hard to make (sterile manufacturing is unforgiving), low-margin, and consequently made by only a small number of qualified producers — chiefly Hikma, Pfizer (via Hospira) and Fresenius Kabi. Because so few plants make any given drug, a single quality problem, recall or line shutdown can tip a life-critical medicine into nationwide shortage; the FDA's drug-shortage list is dominated by exactly these injectables. Hikma is one of the few companies that both supplies many of these drugs and steps up production when peers fail, which makes its manufacturing footprint a genuine chokepoint: the resilience of U.S. hospital pharmacology rests on a handful of injectable makers, and Hikma is one of the load-bearing ones. [verify: generic sterile injectables shortage-prone, Hikma/Pfizer/Fresenius established]

  Hikma Pharmaceuticals PLC (HIK.L) ↗

• Concentration2024

  Hikma's three-legged structure — US/EU injectables, US oral generics, and a branded business across the Middle East and North Africa — is itself a strategic hedge. The MENA branded segment, where Hikma holds strong local distribution and manufacturing built over decades, is a regional moat that few Western generics rivals can replicate, and it cushions the brutal price competition of the U.S. generics market. The company's manufacturing spans the US, Europe and the Middle East, giving it multi-region sterile capacity at a time when regulators increasingly worry that critical-drug production is too concentrated in a few countries. Hikma is thus both a beneficiary of, and a partial answer to, the policy push to diversify and reshore essential-medicine manufacturing.

  Hikma Pharmaceuticals PLC (HIK.L) ↗